
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.

Dr Fleming is a senior business analyst at Lifescience Dynamics in London. She earned a doctorate in cancer biology from the Institute of Cancer Research in London before transitioning to work in biopharma consulting. She has supported clients across several indications, including MDD, bringing expertise in competitive intelligence.

Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.